New MSK research discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers; examined how tumor-associated macrophages might be turned against cancer; acquired new insights into joint inflammation in rheumatoid arthritis; developed a systems-level platform called epichaperomics to map changes in interactors among thousands of proteins involved in cancer-related processes; and investigated how artificial intelligence could help diagnose an invasive form of breast cancer.

Memorial Sloan Kettering researchers are studying how drugs that reverse malfunctioning proteins may treat disease.

A study from investigators in the Sloan Kettering Institute uncovers the details of how a key protein called GRP94 becomes disrupted, leading to cancer and other diseases.

Collaborative team advances a new approach for imaging a drug that’s been developed to stop cancer growth.

A targeted approach being developed to treat certain cancers may also be effective for Alzheimer’s disease.

A family of drugs developed at MSK targets disrupted processes in cells in diseases related to aging.

An innovative collaboration between basic scientists and clinical researchers has led to a promising new drug for AML.

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.

A small molecule discovered at MSK called PU-H71 blocks the growth of cancer cells and enables doctors to image tumors.

A dynamic mix of experts in biology, chemistry, and medicine come together in the Sloan Kettering Institute lab of chemical biologist Gabriella Chiosis to investigate chaperone proteins involved in cancer.